Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Systemic administration of β-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer.

Zhang M, Chun L, Sandoval V, Graor H, Myers J, Nthale J, Rauhe P, Senders Z, Choong K, Huang AY, Kim J.

Oncoimmunology. 2017 Oct 30;7(2):e1387347. doi: 10.1080/2162402X.2017.1387347. eCollection 2018.

2.

A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.

Yu X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR, Wang XY.

Cancer Res. 2013 Apr 1;73(7):2093-103. doi: 10.1158/0008-5472.CAN-12-1740. Epub 2013 Jan 18.

4.

Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.

da Cunha A, Antoniazi Michelin M, Cândido Murta EF.

Immunol Lett. 2016 Sep;177:25-37. doi: 10.1016/j.imlet.2016.07.009. Epub 2016 Jul 14.

PMID:
27423825
5.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

6.

Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer.

Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J.

Clin Cancer Res. 2010 Nov 1;16(21):5153-64. doi: 10.1158/1078-0432.CCR-10-0820. Epub 2010 Sep 20.

7.

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, Slingluff CL Jr, Mullins DW.

J Immunother. 2010 Nov-Dec;33(9):965-74. doi: 10.1097/CJI.0b013e3181fb045d.

8.

Antitumor activity of orally administered maitake α-glucan by stimulating antitumor immune response in murine tumor.

Masuda Y, Nakayama Y, Tanaka A, Naito K, Konishi M.

PLoS One. 2017 Mar 9;12(3):e0173621. doi: 10.1371/journal.pone.0173621. eCollection 2017.

9.

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6. doi: 10.1073/pnas.1108121108. Epub 2011 Oct 3.

10.

Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ.

J Immunol. 2013 Feb 15;190(4):1873-81. doi: 10.4049/jimmunol.1201989. Epub 2013 Jan 11.

11.

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Guo Z, Wang H, Meng F, Li J, Zhang S.

J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y.

12.

USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.

Hong B, Li H, Lu Y, Zhang M, Zheng Y, Qian J, Yi Q.

Mol Cancer. 2014 May 31;13:132. doi: 10.1186/1476-4598-13-132.

13.

Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.

de Melo FM, Braga CJ, Pereira FV, Maricato JT, Origassa CS, Souza MF, Melo AC, Silva P, Tomaz SL, Gimenes KP, Scutti JA, Juliano MA, Zamboni DS, Câmara NO, Travassos LR, Ferreira LC, Rodrigues EG.

Immunol Cell Biol. 2015 Jan;93(1):86-98. doi: 10.1038/icb.2014.74. Epub 2014 Sep 16.

PMID:
25223833
14.

Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer.

Bear AS, Kennedy LC, Young JK, Perna SK, Mattos Almeida JP, Lin AY, Eckels PC, Drezek RA, Foster AE.

PLoS One. 2013 Jul 23;8(7):e69073. doi: 10.1371/journal.pone.0069073. Print 2013.

15.

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F.

J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15.

16.

Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.

Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M.

Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018.

17.
18.

The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4+ T-cell-mediated antitumor memory immune response.

He K, Liu P, Xu LX.

Cell Death Dis. 2017 Mar 23;8(3):e2703. doi: 10.1038/cddis.2017.125.

19.

Mycobacterium bovis Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function.

Lardone RD, Chan AA, Lee AF, Foshag LJ, Faries MB, Sieling PA, Lee DJ.

Front Immunol. 2017 Aug 11;8:965. doi: 10.3389/fimmu.2017.00965. eCollection 2017.

20.

Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.

Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, Wang J, Xu F, Cheng L, Zhang X, Dai L, Chen X, Zhang S, Yang Y, Yu D, Wei Y, Deng H.

BMC Cancer. 2014 Jan 29;14:48. doi: 10.1186/1471-2407-14-48.

Supplemental Content

Support Center